$ALT
Altimmune, Inc.

2014 Q4 Form 10-Q Financial Statement

#000114420414065679 Filed on November 06, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $1.830M $8.00 $31.00
YoY Change -49.86% -74.19% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.620M $3.190M $4.090M
YoY Change -42.79% -22.0% 24.7%
% of Gross Profit
Research & Development $1.790M $1.729M $2.556M
YoY Change -56.34% -32.37% -50.25%
% of Gross Profit
Depreciation & Amortization $40.00K $37.13K $44.59K
YoY Change 0.0% -16.75% -38.45%
% of Gross Profit
Operating Expenses $4.450M $4.958M $6.687M
YoY Change -48.97% -25.85% -21.2%
Operating Profit -$2.624M -$3.996M -$3.199M
YoY Change -48.23% 24.91% 78.69%
Interest Expense $10.00K $46.93K $89.82K
YoY Change -98.48% -47.75% -20.18%
% of Operating Profit
Other Income/Expense, Net $0.00 -$607.3K -$717.9K
YoY Change -15.4% -144.91%
Pretax Income -$2.620M -$4.603M -$3.917M
YoY Change -40.59% 17.52% 1941.59%
Income Tax $10.00K $25.07K $30.00K
% Of Pretax Income
Net Earnings -$2.629M -$4.628M -$3.946M
YoY Change -40.57% 17.3% 1744.42%
Net Earnings / Revenue -143.68% -57855437.5% -12728667.74%
Basic Earnings Per Share -$0.04 -$0.08 -$0.08
Diluted Earnings Per Share -$0.04 -$0.08 -$0.08
COMMON SHARES
Basic Shares Outstanding 63.37M shares 56.44M shares 52.31M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.60M $19.60M $15.90M
YoY Change 77.14% 23.27% 8.16%
Cash & Equivalents $18.64M $19.62M $15.94M
Short-Term Investments $6.400M $6.400M
Other Short-Term Assets $200.0K $700.0K $200.0K
YoY Change 0.0% 250.0% -50.0%
Inventory
Prepaid Expenses
Receivables $400.0K $300.0K $1.600M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $19.25M $20.59M $17.77M
YoY Change 34.25% 15.87% -12.82%
LONG-TERM ASSETS
Property, Plant & Equipment $325.8K $362.5K $429.5K
YoY Change -15.62% -15.61% -22.34%
Goodwill $2.348M $2.348M $2.348M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $53.38K $53.38K $74.59K
YoY Change -18.7% -28.43% -42.93%
Total Long-Term Assets $2.728M $2.764M $2.853M
YoY Change -2.59% -3.09% -5.93%
TOTAL ASSETS
Total Short-Term Assets $19.25M $20.59M $17.77M
Total Long-Term Assets $2.728M $2.764M $2.853M
Total Assets $21.98M $23.35M $20.62M
YoY Change 28.23% 13.24% -11.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $391.4K $282.0K $1.159M
YoY Change -65.31% -75.67% -37.23%
Accrued Expenses $1.200M $2.600M $2.600M
YoY Change -62.5% 0.0% -18.75%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due $746.1K $993.3K $1.000M
YoY Change -25.39% -0.67% 46.67%
Total Short-Term Liabilities $2.582M $3.885M $5.413M
YoY Change -62.01% -28.24% -22.34%
LONG-TERM LIABILITIES
Long-Term Debt $974.4K
YoY Change -44.77%
Other Long-Term Liabilities $493.1K $507.1K $592.0K
YoY Change -16.24% -14.35% 2.13%
Total Long-Term Liabilities $493.1K $507.1K $1.566M
YoY Change -62.61% -67.63% -33.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.582M $3.885M $5.413M
Total Long-Term Liabilities $493.1K $507.1K $1.566M
Total Liabilities $3.704M $5.244M $9.265M
YoY Change -62.22% -43.4% -14.69%
SHAREHOLDERS EQUITY
Retained Earnings -$220.3M -$217.7M -$205.9M
YoY Change 4.73% 5.71% 4.34%
Common Stock $238.8M $236.0M $217.5M
YoY Change 9.59% 8.51% 3.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.27M $18.11M $11.35M
YoY Change
Total Liabilities & Shareholders Equity $21.98M $23.35M $20.62M
YoY Change 28.23% 13.24% -11.93%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$2.629M -$4.628M -$3.946M
YoY Change -40.57% 17.3% 1744.42%
Depreciation, Depletion And Amortization $40.00K $37.13K $44.59K
YoY Change 0.0% -16.75% -38.45%
Cash From Operating Activities -$3.520M -$2.120M -$680.0K
YoY Change -43.77% 211.76% -139.31%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K -$10.00K
YoY Change 0.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 -$10.00K -$10.00K
YoY Change 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.550M 10.50M 840.0K
YoY Change 222.78% 1150.0% -30.58%
NET CHANGE
Cash From Operating Activities -3.520M -2.120M -680.0K
Cash From Investing Activities 0.000 -10.00K -10.00K
Cash From Financing Activities 2.550M 10.50M 840.0K
Net Change In Cash -970.0K 8.370M 150.0K
YoY Change -82.27% 5480.0% -94.9%
FREE CASH FLOW
Cash From Operating Activities -$3.520M -$2.120M -$680.0K
Capital Expenditures $0.00 -$10.00K -$10.00K
Free Cash Flow -$3.520M -$2.110M -$670.0K
YoY Change -43.77% 214.93% -138.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2014Q3 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
USD
CY2013Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
51663 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217653920 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
18106043 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23349714 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1470 USD
CY2014Q3 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
303667 USD
CY2013Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
2199525 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
231491 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
14339108 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
386068 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
65660 USD
CY2013Q4 us-gaap Goodwill
Goodwill
2348453 USD
CY2013Q4 us-gaap Assets
Assets
17139289 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1128172 USD
CY2013Q4 pip Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
3182687 USD
CY2014Q3 us-gaap Deferred Revenue
DeferredRevenue
56786 USD
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
341723 USD
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
507072 USD
CY2014Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
851793 USD
CY2014Q3 us-gaap Liabilities
Liabilities
5243671 USD
CY2013Q4 us-gaap Liabilities
Liabilities
9803577 USD
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
661360 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
20585419 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
362458 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53384 USD
CY2014Q3 us-gaap Goodwill
Goodwill
2348453 USD
CY2014Q3 us-gaap Assets
Assets
23349714 USD
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
282024 USD
CY2014Q3 pip Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2552674 USD
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
999996 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3884806 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6795981 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
588745 USD
CY2013Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1688572 USD
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62215986 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52304246 shares
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
6222 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
5230 USD
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
235979613 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
217877117 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-218710 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210327925 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
7335712 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17139289 USD
CY2014Q3 us-gaap Depreciation
Depreciation
37125 USD
CY2014Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
USD
CY2013Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
1091740 USD
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
730279 USD
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-225872 USD
CY2013Q4 us-gaap Billed Contract Receivables
BilledContractReceivables
1427113 USD
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52304246 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62215986 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Contracts Revenue
ContractsRevenue
8363909 USD
us-gaap Contracts Revenue
ContractsRevenue
14258680 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1728929 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2556383 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7528616 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11192403 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3192427 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4086348 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8289788 USD
CY2013Q3 us-gaap Depreciation
Depreciation
44593 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
4958481 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
6687324 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3996030 USD
CY2014Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
8 USD
CY2013Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
31 USD
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
690 USD
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
2470 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
46938 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
89817 USD
us-gaap Interest Expense
InterestExpense
174046 USD
us-gaap Interest Expense
InterestExpense
289635 USD
CY2013Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-628622 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3506 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-717901 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
289877 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1472246 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4603367 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3917083 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7277890 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7243891 USD
CY2014Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
25068 USD
CY2013Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
28804 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
48105 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
49753 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-4628435 USD
us-gaap Net Income Loss
NetIncomeLoss
-7325995 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-284937 USD
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58952731 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52166733 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55577550 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50105641 shares
CY2014Q3 us-gaap Contracts Revenue
ContractsRevenue
962451 USD
CY2013Q3 us-gaap Contracts Revenue
ContractsRevenue
3488142 USD
CY2014Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5869 USD
CY2013Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
164 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-7162 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2782 USD
CY2014Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4634304 USD
CY2013Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3945723 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7333157 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7296426 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-3945887 USD
us-gaap Depreciation
Depreciation
139049 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
48105 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
49753 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
68130 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
104726 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
5393 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3500 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1427113 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2432641 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-1895858 USD
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-2501117 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23869 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-313384 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-846090 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-588086 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-773517 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
203951 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-909939 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4951585 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-911712 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
92269 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
84579 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3500 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-84269 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-81079 USD
us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
-749997 USD
us-gaap Proceeds From Repayments Of Other Long Term Debt
ProceedsFromRepaymentsOfOtherLongTermDebt
-499998 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-1091740 USD
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-1330507 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
683325 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15341264 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6068891 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14182852 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4238386 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-7585 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12701517 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19620392 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15943399 USD
us-gaap Interest Paid
InterestPaid
105916 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-3713 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9139413 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3241882 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10480979 USD
us-gaap Interest Paid
InterestPaid
184909 USD
us-gaap Net Income Loss
NetIncomeLoss
-7293644 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1172703 USD
us-gaap Share Based Compensation
ShareBasedCompensation
957261 USD
us-gaap Use Of Estimates
UseOfEstimates
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><em>Use of Estimates</em></p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">&#160;</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our derivative instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</p> </div>
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4495556 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11600000 shares
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
280720 USD
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
304672 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1172703 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
957261 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1357755 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
205000 shares
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1700000 USD
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10900000 shares
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11600000 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10900000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2013Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
7928807 USD
CY2013Q4 us-gaap Derivative Assets
DerivativeAssets
7928807 USD
CY2013Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1740235 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
464703 USD
CY2014Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
851793 USD
CY2012Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1295613 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-1181575 USD
CY2013Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
2477188 USD
CY2014Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
6429125 USD
CY2014Q3 us-gaap Derivative Assets
DerivativeAssets
6429125 USD
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63373584 shares
dei Trading Symbol
TradingSymbol
PIP
CY2014Q3 pip Billed And Unbilled Accounts Receivable Net
BilledAndUnbilledAccountsReceivableNet
300000 USD
CY2014Q3 us-gaap Billed Contract Receivables
BilledContractReceivables
USD
CY2009Q3 pip Warrant Expiration Date
WarrantExpirationDate
2015-01-28
CY2012Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2500000 USD
CY2014Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
249999 USD
CY2014Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
750007 USD
CY2014Q3 pip Long Term Debt Excluding Discount
LongTermDebtExcludingDiscount
1000006 USD
CY2014Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
993322 USD
CY2014Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
USD
CY2014Q3 us-gaap Long Term Debt
LongTermDebt
993322 USD
dei Entity Registrant Name
EntityRegistrantName
PHARMATHENE, INC
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001326190
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31

Files In Submission

Name View Source Status
0001144204-14-065679-index-headers.html Edgar Link pending
0001144204-14-065679-index.html Edgar Link pending
0001144204-14-065679.txt Edgar Link pending
0001144204-14-065679-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
pip-20140930.xml Edgar Link completed
pip-20140930.xsd Edgar Link pending
pip-20140930_cal.xml Edgar Link unprocessable
pip-20140930_def.xml Edgar Link unprocessable
pip-20140930_lab.xml Edgar Link unprocessable
pip-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v392097_10q.htm Edgar Link pending
v392097_ex10-61.htm Edgar Link pending
v392097_ex31-1.htm Edgar Link pending
v392097_ex31-2.htm Edgar Link pending
v392097_ex32-1.htm Edgar Link pending
v392097_ex32-2.htm Edgar Link pending